The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Inequalities in biomarker testing
Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, talks on inequalities in access to biomarker testing and targeted treatments. Patients with lung cancer who were from a poorer socioeconomic background were found to have worse access to biomarker testing. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Alastair Greystoke, MBChB, MSc, PhD, MRCP, has received consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, Foundation Medicine, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and has received research funding from AstraZeneca.
